Project Grant HT94252410467
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$495K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
The Defense Health Agency awarded a $697,766 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Murdoch Children's Research Institute in Australia. The grant, awarded on July 15, 2024, will fund a 3-year research project titled "BRAIN CHARTS IN CHILDREN AND ADOLESCENTS WITH NEUROFIBROMATOSIS TYPE 1". The project aims to conduct biomedical research to better understand and characterize brain development in children and adolescents with...
The U.S. Defense Health Agency has awarded a $367,622 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to St. Vincent's Institute of Medical Research, a foreign-owned non-profit organization based in Australia. The grant supports a 2-year research project focused on studying the reprogramming of mRNA translation as a driver of drug resistance in ovarian cancer. The research aims to transform healthcare for military service members and the broader public...
The Department of the Army Medical Command awarded $1.393 million to the Children's Research Institute under the Military Medical Research and Development federal grant program (CFDA 12.420) to support an early-phase study evaluating MEK and MDM2 inhibition in patients with neurofibromatosis type 1 and premalignant and malignant peripheral nerve sheath tumors. The Children's Research Institute will conduct the clinical trial through September 2026 to investigate medical solutions for...
The federal Project Grant award of $591,096.00, awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), supports research by the St. Vincent's Institute of Medical Research in Australia. The goal of the project is to prevent bone marrow failure in Fanconi anemia through inhibition of the FANCM gene. The award period runs from July 15, 2025 to July 14, 2028. The research aims to develop innovative gene correction techniques and explore...
This $713,818 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the Research Institute at Nationwide Children's Hospital in Columbus, Ohio to characterize novel patient-specific modeling systems for NF2 disease research and therapeutic testing. The project will be conducted from September 1, 2024 through August 31, 2027. The Research Institute has extensive experience delivering federal research...
The U.S. Defense Health Agency awarded a $777,659 Project Grant to the Children's Research Institute in Washington, D.C. under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research to transform healthcare for military service members, veterans, and the public, with a focus on innovative research addressing critical health challenges. Specifically, the award will fund the "Use of ProResolution and Restorative Pharmacology...
The Defense Health Agency awarded a $1,528,727.00 Project Grant to Children's Research Institute, a subsidiary of Children's National Medical Center, to develop SGT-53, a novel nanomedicine that crosses the blood-brain barrier and augments immunotherapeutic response in pediatric brain cancers. This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for Service Members and the...
The U.S. Defense Health Agency awarded a $437,975 Project Grant to the University of New South Wales, doing business as The University of NSW, to conduct research on "TARGETING THE NOVEL LONG NONCODING RNA PRKCQ-AS1 FOR CANCER THERAPY". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform healthcare for U.S. Service Members and the public. The funded research aims...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
This $154,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the Arkansas Children's Research Institute's research on the unique DNA methylation landscape of deregulated enhancers in CBFA2T3-GLIS2 positive pediatric acute megakaryoblastic leukemia. The award period runs from November 1, 2024 to October 31, 2026. The research aims to advance the scientific understanding of this rare pediatric cancer subtype and...